Principal Software Engineer
Genesis TherapeuticsSalary not specified
- Full Time
- Senior (5 to 8 years), Expert & Leadership (9+ years)
$135,000 – $190,000Compensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Biotechnology, Drug Discovery, HealthcareIndustries
Requirements
Candidates must possess a minimum of 8 years of related experience, holding a Bachelor’s degree, or 6 years with a Master’s degree, or a PhD with 3 years of experience, and demonstrate technical acumen in developing and maintaining machine learning systems, particularly those cloud-based and handling large datasets. Strong Python software skills, working knowledge of chemistry and biology concepts, and the ability to communicate effectively with ML engineers are also required. Experience with scientific computing environments, such as SLURM, and familiarity with cloud computing are highly valued.
Responsibilities
The Software Engineer II/Sr Software Engineer will be responsible for developing training data workflows for machine learning models, creating and maintaining scalable deployment of machine learning technologies, collaborating with cross-functional teams on drug discovery, providing software development support throughout the ML model lifecycle, including designing efficient data pipelines, benchmarking models, and deploying systems to AWS and utilizing Kubernetes in collaboration with cloud engineers. They will also perform code reviews, maintain software best practices, collaborate with ML scientists to understand requirements, and clearly communicate work in meetings and demos.
Skills
Python
Machine Learning
Cloud Computing
AWS
Kubernetes
Scientific Computing
Lab Environments
SLURM
Chemistry
Biology
DevOps
Software Development
Data Pipelines
Model Benchmarking
Version Control
Testing
Documentation
Axsome Therapeutics Inc
Develops therapies for CNS disorders
About Axsome Therapeutics Inc
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.
Key Metrics
New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees